Akso Health Group Sponsored ADR (AHG) AI Stock Analysis

• Market Cap: $199.64M
• Dividend Yield: N/A
• Average Volume (3M): 35.76K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.14
• Revenue Growth: -81.66%
• EPS Growth: -214.54%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 78
• Industry: Medical Distributors
• EPS (TTM): -0.19
• Shares Outstanding: 145,723,650
• 10 Day Avg. Volume: 79,896
• 30 Day Avg. Volume: 35,761
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 159.44
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall stock score for Akso Health Group is low due to significant challenges in profitability and revenue stability. The technical analysis points to negative momentum, while the valuation is weak with a negative P/E ratio. The recent market reaction post-earnings call was negative, further impacting the score. Without positive corporate events or earnings call highlights, the outlook remains cautious.

Akso Health Group Sponsored ADR Business Overview & Revenue Model

Company Description

Akso Health Group Sponsored ADR (AHG) is a healthcare company focused on providing comprehensive health services primarily in the fields of traditional Chinese medicine and integrated healthcare solutions. The company operates in various sectors including healthcare services, wellness management, and health-related technology, aiming to enhance patient care and promote overall well-being through innovative practices and treatments.

How the Company Makes Money

Akso Health Group generates revenue through a diversified model that includes providing healthcare services such as traditional Chinese medicine consultations, wellness management programs, and integrated healthcare solutions. The company collaborates with healthcare institutions and leverages its expertise in both traditional and modern medical practices to offer a wide range of services. Revenue streams are primarily driven by patient consultations, treatment programs, and strategic partnerships with healthcare providers and technology firms that enhance its service offerings. Key factors contributing to its earnings include the growing demand for alternative medicine, expansion into new markets, and the integration of technology in healthcare services to improve efficiency and patient outcomes.

Akso Health Group Sponsored ADR Financial Statement Overview

Summary

Akso Health Group faces challenges with profitability and revenue stability. While its balance sheet shows a strong equity position, the lack of comprehensive debt information introduces uncertainty in financial leverage assessment. Cash flow has improved recently, but historical volatility poses a risk. Overall, the company needs to address its revenue and profitability issues to enhance financial health.

Income Statement

The company has experienced significant revenue volatility, with a steep decline in recent years. The net profit margin is severely negative due to substantial net losses, indicating poor profitability. There is no gross profit data to assess cost efficiency, and EBIT/EBITDA margins are unavailable for additional insights.

Balance Sheet

The equity ratio is strong, indicating a solid equity base relative to total assets. However, the lack of debt data prevents a full assessment of leverage. Stockholders' equity has increased recently, but the company has a history of equity fluctuations.

Cash Flow

The company has shown inconsistent operating cash flows, with recent positive figures. Free cash flow has been volatile, with significant growth over the past year, albeit from a low base. The cash flow to net income ratio is unreliable due to negative net income.

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
2.41M	13.18M	6.31M	1.75M	11.44M
	Gross Profit
122.13K	1.27M	916.23K	1.21M	6.44M
	EBIT
-8.64M	-14.27M	-15.13M	-27.15M	-36.83M
	EBITDA
-8.50M	-14.25M	-3.26M	-2.07M	-18.80M
	Net Income Common Stockholders
-9.46M	-13.08M	-16.85M	-31.55M	-71.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
85.17M	7.92M	21.93M	15.13M	10.93M
	Total Assets
142.02M	20.46M	50.68M	31.69M	78.38M
	Total Debt
2.00M	9.69M	37.20M	10.00M	20.79M
	Net Debt
-85.17M	1.76M	15.27M	-5.13M	9.87M
	Total Liabilities
3.59M	11.62M	38.39M	14.41M	30.28M
	Stockholders Equity
138.37M	8.73M	12.28M	17.27M	48.10M
Cash Flow		Free Cash Flow
1.35M	-3.25M	-8.63M	10.06M	-56.18M
	Operating Cash Flow
1.35M	-3.25M	-8.63M	10.06M	-55.87M
	Investing Cash Flow
-54.72M	18.47M	-19.96M	-662.00	12.78M
	Financing Cash Flow
131.65M	-27.51M	34.78M	-9.04M	-3.97M

Akso Health Group Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AHG, the sentiment is Positive. The current price of 1.37 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.33, and above the 200-day MA of 1.07, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.34 is Neutral, neither overbought nor oversold. The STOCH value of 63.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AHG.

Akso Health Group Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EHC	72 Outperform	$9.77B	22.23	24.52%	0.65%	11.91%	28.47%
SEM	66 Neutral	$2.24B	10.80	13.35%	2.79%	-0.63%	-13.10%
SLS	56 Neutral	$92.73M	―	-535.10%	―	―	54.63%
BNR	52 Neutral	$50.82M	―	-56.29%	―	-10.56%	41.02%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
IMRN	46 Neutral	$10.43M	―	-52.79%	―	82.77%	-87.95%
AHG	45 Neutral	$199.64M	―	-6.83%	―	-81.66%	-214.54%